MOR MorphoSys AG ADRs

MorphoSys AG engages in the development of therapeutic antibodies to cure inflammatory and autoimmune diseases, as well as cancer and infectious diseases. The company operates through two business segments; Partnered Discovery and Proprietary Development. This is an ADR of a company whose stock trades outside of the U.S. as the symbol GF:MOR.

$3.99  +0.05 (1.27%)
As of 03/27/2023 11:30:07 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  
IPO date:  04/19/2018
Outstanding shares:  136,927,772
Average volume:  73,857
Market cap:   $539,495,422
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%